MiNK Therapeutics (INKT) Earnings Analysis

MiNK Therapeutics (INKT) next reports earnings on 2026-08-13, consensus EPS -0.6 USD. Last quarter (2026-05-15) it beat with EPS -0.57 USD vs -0.77 USD est (+26%). It has beaten estimates in 4/7 recent quarters (57%). Trailing P/E -3.62.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does INKT next report earnings?

Next earnings date2026-08-13
Consensus EPS estimate-0.6 USD
Revenue estimaten/a

INKT earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-15-0.57 USD-0.77 USD+26%Beat
2026-03-17-0.52 USD-0.68 USD+23.5%Beat
2025-11-14-0.65 USD-0.86 USD+24.4%Beat
2025-08-14-1.06 USD-0.55 USD-92.7%Miss
2025-05-15-0.7 USD-0.61 USD-14.8%Miss
2025-03-18-0.62 USD-0.5 USD-24%Miss
2024-11-14-0.5 USD-0.8 USD+37.5%Beat

Beat rate: 4/7 (57%) over reported quarters with consensus data.

INKT valuation and analyst view

Trailing P/E-3.62
Trailing EPS-2.59899 USD
Price / book-3.87
Dividend yield0.00%
Market cap0.05B
Analyst consensusBuy (4 buy / 1 hold / 0 sell)

Related research pages

Frequently asked questions

When is MiNK Therapeutics (INKT)'s next earnings date?

MiNK Therapeutics is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.6 USD.

Did INKT beat earnings last quarter?

In its 2026-05-15 report, INKT posted EPS of -0.57 USD versus a -0.77 USD estimate — a beat of 26%.

What is INKT's earnings track record?

Over the last 7 reported quarters with consensus data, INKT beat estimates 4 times (57%).

What is INKT's current P/E ratio and EPS?

INKT trades at a trailing P/E of -3.62 on trailing EPS of -2.5989852021675697 USD.

What do analysts rate INKT?

Analyst consensus is "Buy" across 5 ratings (0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell).